MRVI
Maravai LifeSciences Holdings, Inc.
MRVI offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over MRVI overall, supported by stronger fundamentals and lower modeled downside.
MRVI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
MRVI's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MRVI PE Valuation
MRVI has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MRVI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect MRVI's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
MRVI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.43 | +$0.44 |
| Q2 2026 | -$0.52 | +$0.87 |
| Q1 2026 | -$0.71 | +$0.46 |
| Q4 2025 | -$0.90 | +$0.15 |
| Q3 2025 | -$0.87 | +$0.77 |
| Q2 2025 | -$1.39 | -$0.40 |
| Q1 2025 | -$1.17 | -$0.18 |
| Q4 2024 | -$1.05 | -$0.15 |
MRVI is still losing money, but far less than before: $0.43 per share over the past year, against $1.64 at its worst in late 2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over MRVI on earnings quality, reporting a profit while its opponent remains loss making.
MRVI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $45.9M | +10% |
| Q2 2026 | $51.4M | +8.5% |
| Q1 2026 | $65.8M | +41% |
| Q4 2025 | $49.9M | -12% |
| Q3 2025 | $41.6M | -36% |
| Q2 2025 | $47.4M | -35% |
| Q1 2025 | $46.9M | -27% |
| Q4 2024 | $56.6M | -24% |
MRVI's revenue is recovering but still below its 2022 peak: $46M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -45% | +54 points |
| Q2 2026 | -29% | +111 points |
| Q1 2026 | -3.3% | +102 points |
| Q4 2025 | -118% | -51 points |
| Q3 2025 | -99% | +161 points |
| Q2 2025 | -140% | -127 points |
| Q1 2025 | -105% | -76 points |
| Q4 2024 | -67% | -57 points |
MRVI's operating margin was −45% last quarter, up 54 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MRVI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over MRVI on profitability, with a higher operating margin.
MRVI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.5M | +$22.6M |
| Q2 2026 | $3.6M | +$16.8M |
| Q1 2026 | $4.2M | +$18.9M |
| Q4 2025 | -$24.9M | -$4.4M |
| Q3 2025 | -$18.1M | -498% |
| Q2 2025 | -$13.1M | -267% |
| Q1 2025 | -$14.6M | -$493K |
| Q4 2024 | -$20.5M | -$11.5M |
MRVI's free cash flow was −$13M over the past year, against −$66M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MRVI on cash generation, producing positive trailing cash flow while its opponent burns cash.
MRVI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +1.1M shares |
| 1 year | +3% | +4.4M shares |
| 3 years | +13% | +17.1M shares |
| 5 years | +33% | +36.8M shares |
| Available history | +54% | +52.4M shares |
MRVI has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MRVI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -5.9x | Net Cash |
| Q3 2023 | -0.5x | Net Cash |
| Q2 2023 | -0.2x | Net Cash |
| Q1 2023 | -0.2x | Net Cash |
| Q4 2022 | -0.2x | Net Cash |
| Q3 2022 | -0.1x | Net Cash |
| Q2 2022 | -0.0x | Net Cash |
| Q1 2022 | 0.2x | Very low |
MRVI has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
MRVI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.8 | Neutral |
| Stochastic | 55.9 | Neutral |
MRVI's weekly RSI is 59 (neutral) and its Stochastic is 56 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MRVI PE vs Healthcare Sector
| Metric | MRVI | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MRVI has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MRVI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.51 | 2.3% above |
| 20 week MA | $7.09 | 8.3% above |
| 50 week MA | $5.11 | 50% above |
| 100 week MA | $4.09 | 88% above |
| 200 week MA | $6.78 | 13% above |
MRVI has climbed back above all five of its weekly moving averages, and it's now 13% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
MRVI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.9 | $29.7 | -0.5% |
| 2021 | $29.7 | $42.0 | +41% |
| 2022 | $42.0 | $14.0 | -67% |
| 2023 | $14.0 | $6.55 | -53% |
| 2024 | $6.55 | $5.50 | -16% |
| 2025 | $5.50 | $3.27 | -41% |
| 2026 YTD | $3.27 | $7.68 | +135% |
MRVI has the edge over OSCR on returns for 2026, with the stronger performance.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.